BCMA-Targeted Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: Three Approvals, Many Questions
Three newly approved antibody drugs give doctors practical options for treating advanced multiple myeloma patients who've exhausted other therapies.
This review from UT Southwestern analyzes the landscape of three approved BCMA bispecific antibodies in relapsed/refractory myeloma, highlighting efficacy, safety profiles, and the many remaining clinical questions around sequencing, resistance, and long-term outcomes. It provides a practical framework for clinicians navigating rapidly expanding therapeutic options in this heavily pre-treated population.
What the study was
- Study design
- Review
- Population
- Relapsed/refractory multiple myeloma patients treated with BCMA-targeted bispecific antibodies
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- The Oncologist
Why it surfaced
Timely review of three FDA-approved BCMA bispecifics in RRMM; clinically relevant for hematology oncology practice but does not present new data; abstract-only with no new primary endpoints.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.